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PRIMARY RESEARCH
Vitamin E δ-tocotrienol sensitizes human 
pancreatic cancer cells to TRAIL-induced 
apoptosis through proteasome-mediated 
down-regulation of c-FLIPs
Rony A. Francois1†, Anying Zhang1,2†, Kazim Husain1, Chen Wang1,3, Sean Hutchinson1, Michael Kongnyuy1, 
Surinder K. Batra4, Domenico Coppola5, Said M. Sebti6 and Mokenge P. Malafa1,6*
Abstract 
Background: Vitamin E δ-tocotrienol (VEDT), a vitamin E compound isolated from sources such as palm fruit and 
annatto beans, has been reported to have cancer chemopreventive and therapeutic effects.
Methods: We report a novel function of VEDT in augmenting tumor necrosis factor-related apoptosis-inducing 
ligand- (TRAIL-) induced apoptosis in pancreatic cancer cells. The effects of VEDT were shown by its ability to trigger 
caspase-8-dependent apoptosis in pancreatic cancer cells.
Results: When combined with TRAIL, VEDT significantly augmented TRAIL-induced apoptosis of pancreatic cancer 
cells. VEDT decreased cellular FLICE inhibitory protein (c-FLIP) levels without consistently modulating the expression of 
decoy death receptors 1, 2, 3 or death receptors 4 and 5. Enforced expression of c-FLIP substantially attenuated VEDT/
TRAIL-induced apoptosis. Thus, c-FLIP reduction plays an important part in mediating VEDT/TRAIL-induced apoptosis. 
Moreover, VEDT increased c-FLIP ubiquitination and degradation but did not affect its transcription, suggesting that 
VEDT decreases c-FLIP levels through promoting its degradation. Of note, degradation of c-FLIP and enhanced TRAIL-
induced apoptosis in pancreatic cancer cells were observed only with the anticancer bioactive vitamin E compounds 
δ-, γ-, and β-tocotrienol but not with the anticancer inactive vitamin E compounds α-tocotrienol and α-, β-, γ-, and 
δ-tocopherol.
Conclusions: c-FLIP degradation is a key event for death receptor-induced apoptosis by anticancer bioactive vitamin 
E compounds in pancreatic cancer cells. Moreover, VEDT augmented TRAIL inhibition of pancreatic tumor growth and 
induction of apoptosis in vivo. Combination therapy with TRAIL agonists and bioactive vitamin E compounds may 
offer a novel strategy for pancreatic cancer intervention.
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Background
Pancreatic ductal adenocarcinoma represents a major 
healthcare problem, with a high fatality rate and increas-
ing incidence, and is likely to increase from the fourth- 
to the second-leading cause of cancer deaths in the US 
by 2030 [1–4]. Escape from apoptosis (programed cell 
death) is a characteristic of pancreatic cancer cells, con-
tributing to their resistance to currently available inter-
ventions [5, 6]. !erefore, targeting apoptosis resistance 
is an important strategy to improve pancreatic cancer 
outcomes.
Apoptosis is controlled by 2 major signaling path-
ways: the extrinsic pathway, initiated by death receptors, 
and the intrinsic pathway, initiated via the mitochon-
dria [7, 8]. Crosstalk between these 2 pathways is medi-
ated by signaling involving the proapoptotic protein Bid 
[9]. !e activation of the extrinsic death receptor-medi-
ated apoptosis pathway relies on a death ligand (e.g., 
tumor necrosis factor-related apoptosis-inducing ligand 
[TRAIL]) binding to its corresponding death receptors 
[10]. Activation of the extrinsic death receptor-mediated 
apoptotic pathway has received attention as a potential 
strategy for cancer treatment because its activation pref-
erentially induces apoptosis in transformed or malignant 
cells but not in most normal cells. Recombinant human 
TRAIL and the agonist antibodies against death recep-
tor 4 (DR4) and death receptor 5 (DR5), which directly 
activate extrinsic apoptotic pathways, are being tested in 
early-phase clinical trials. However, recent studies have 
shown that many types of cancer cells, including pan-
creatic ductal adenocarcinoma cells, are resistant to the 
apoptotic effects of TRAIL [11–13], suggesting that treat-
ment with TRAIL alone may not be sufficient for treat-
ing pancreatic cancer. !erefore, sensitizers capable of 
overcoming TRAIL resistance in pancreatic cancer cells 
are needed to establish more effective TRAIL-based pan-
creatic cancer therapies.
Tocotrienols (α-, β-, δ-, and γ-) are 1 of 2 groups of 
compounds that constitute the vitamin E family [14]. !e 
β-, δ -, and γ-tocotrienols have shown promising efficacy 
in preventing and treating human cancers, including 
pancreatic cancer [15–18]. Vitamin E delta-tocotrienol 
(VEDT) is undergoing early-phase human clinical trials 
for pancreatic cancer intervention. VEDT exhibits pleio-
tropic pancreatic anticancer effects, including induction 
of cell cycle arrest and apoptosis [16, 19] and preven-
tion of angiogenesis and invasion [20–22], demonstrat-
ing VEDT’s potential utility as a pancreatic anticancer 
drug. VEDT also augments gemcitabine activity in pan-
creatic cancer, suggesting its potentiality as an adjunct 
in combination therapy. Multiple targets, including p27, 
K-ras, p53, NF-kB, and VEGF, have been proposed to 
explain the anticancer effects of VEDT [16, 19–22], but 
the underlying molecular mechanisms have not yet been 
fully elucidated.
Here, we show for the first time that VEDT effectively 
sensitizes pancreatic cancer cells but not human pancre-
atic ductal epithelial cells to TRAIL-induced apoptosis, 
suggesting that this combined treatment may provide a 
safe and effective therapeutic strategy against pancreatic 
cancer. Furthermore, we provide novel evidence that the 
prominent sensitizing effect of VEDT on TRAIL-induced 
apoptosis is primarily through inducing cellular FLICE 
inhibitory protein (c-FLIP) degradation. !us our find-
ings highlight a novel mechanism by which VEDT modu-
lates apoptosis in human cancer cells.
Methods and materials
Ethics statement
All experiments were carried out in accordance with 
guidelines set by the Animal Experimental Ethics 
Committee.
Chemicals and reagents
Vitamin E analogs α-, β-, γ-, and δ-tocopherols and 
tocotrienols were kindly gifted by Davos Life Sciences 
(Helios, Singapore). Ethanol was purchased from Aaper 
Alcohol & Chemical (Shelbyville, KY). Recombinant 
human TRAIL was purchased from Invitrogen (Carlsbad, 
CA). FLICE inhibitory protein (FLIP) antibody (NF6) 
was purchased from Alexis Biochemicals (Enzo Life Sci-
ences, Farmingdale, NY). DR5, DR4, DCR1, DCR2, and 
DCR3 antibodies were purchased from Abcam (Cam-
bridge, MA). Caspase-3 (#9662), caspase-8 (#9746), 
PARP (#9542), cleaved caspase 3 (#9661S), cleaved cas-
pase 8 (#9496), cleaved PARP (#5625), and green fluores-
cence protein (GFP) antibodies were purchased from Cell 
Signaling Technology (Beverly, MA). Hemagglutinin- 
(HA-) probe antibody, protein A/G PLUS-Agarose, and 
secondary antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). All cDNA plasmids 
were purchased from Origene (Rockville, MD). !e sul-
forhodamine B- (SRB-) based In Vitro Toxicology Assay 
Kit and all other reagents were purchased from Sigma-
Aldrich (St. Louis, MO) unless otherwise specified.
Cell lines and culture conditions
AsPc-1, BxPc-3, MiaPaCa-2, PANC-1, and SW1990 
human pancreatic cancer cell lines (American Type Cul-
ture Collection, Manassas, VA) were cultured in com-
plete 1 × Dulbecco’s Modified Eagle Medium (DMEM; 
Invitrogen) supplemented with 10% fetal bovine serum 
(HyClone, Logan, UT), penicillin–streptomycin (Medi-
atech, Herndon, VA) at a final concentration of 50  IU/
mL (penicillin), 50  mg/mL (streptomycin), and 2  mM 
-glutamine (Mediatech). AsPc-1 and BxPc-3 cells were 
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cultured in complete RPMI 1640 medium (Invitrogen) 
containing 10% fetal bovine serum, penicillin–strepto-
mycin, 10 mM HEPES buffer (Mediatech), 1 mM sodium 
pyruvate (Invitrogen), and 2  mM -glutamine (Medi-
atech). HPDE6-C7 human pancreatic ductal epithelial 
cells (gift from G. Springett, Moffitt Cancer Center) were 
cultured in keratinocyte serum-free medium (Invitro-
gen) containing the provided epidermal growth factor 
and bovine pituitary extract supplements. Immortalized 
human pancreatic normal epithelial (HPNE) cells (gift 
from P. Campbell, Moffitt Cancer Center) were cultured 
in a mixture of DMEM and M3:F media (INCELL, San 
Antonio, TX) at a ratio of 3 parts DMEM and 1 part 
M3:F media and were supplemented with 5% fetal bovine 
serum. All cell lines were maintained at 37 °C in a humid-
ified incubator with 5%  CO2. Cells were passaged regu-
larly with .05% trypsin-ethylenediaminetetraacetic acid 
(Invitrogen) to maintain logarithmic-phase growth. For 
all experiments, cells were gently detached with Accutase 
enzyme cell detachment medium (eBioscience, San 
Diego, CA) in accordance with the provided protocol, 
with Trypan Blue and hemacytometer used to determine 
viable cell number.
Cell viability and cell survival assay
Cells were seeded in 96-well plates at a density of 3000 
cells/well and allowed to attach overnight. After cells 
were incubated for 72  h with various concentrations of 
drugs  (10−5 to  10−4 M) or ethanol (< 5%) as vehicle con-
trol, media were aspirated and replaced with 20  µL of 
1  mg/mL MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide) and incubated for 2 to 4  h at 
37 °C in a humidified atmosphere of 5%  CO2. Media were 
aspirated, 200  µL of dimethyl sulfoxide were added to 
each well, plates were incubated for 5 min with shaking, 
and absorbance was read at 540  nm. Cell survival was 
determined using the SRB colorimetric assay for cyto-
toxicity in accordance with manufacturer’s instructions. 
!e SRB assay is an established surrogate for cell survival 
[23]. Absorbance was recorded using a microplate reader 
at 565 nm.
Determination of apoptosis
Cells (1 × 106) were seeded in 100-mm tissue cul-
ture dishes and allowed to adhere overnight. Cells 
were treated the following day at varying doses with 
δ-tocotrienol and collected at specific time points to 
assess apoptosis by either terminal deoxynucleotidyl 
transferase-mediated nick end labeling (TUNEL) or 
annexin V staining. Cells were washed with phosphate-
buffered saline (PBS), pelleted, and counted using a 
hemacytometer. For all TUNEL experiments, ~ 1 × 105 
cells were fixed onto a glass slide using a Cytospin III 
centrifuge (!ermo Shandon Inc., Pittsburgh, PA) and 
then fixed in 4% paraformaldehyde in PBS solution 
overnight at 4 °C. Cells were made permeable the next 
day via incubation in 0.1% sodium citrate-0.1% Tri-
ton X-100 solution at 4  °C for 2  min and then labeled 
for apoptotic DNA strand breaks using the in  situ 
cell death detection kit, AP (Roche Applied Science, 
Indianapolis, IN) in accordance with manufacturer’s 
instructions. Cells were stained in Vectashield mount-
ing medium (Vector Laboratories, Burlingame, CA) 
containing DAPI (4,6-diamidino-2-phenylindole) to 
counterstain DNA. Fluorescein-labeled DNA strand 
breaks (TUNEL-positive cells) were then visualized 
using a fluorescence microscope (Leica Microsys-
tems Inc., Bannockburn, IL), and 5 representative pic-
tures of the slide field were taken with a digital camera 
(Diagnostic Instruments, Inc., Sterling Heights, MI). 
TUNEL-positive nuclei (green) were scored and com-
pared with DAPI-stained nuclei (blue) to determine 
the induction percentage of apoptosis for each treat-
ment group. Annexin V and propidium iodide staining 
were performed with the Annexin V-FITC Apoptosis 
Detection Kit I (BD Biosciences) as follows: pelleted 
cells were washed twice with cold PBS and then briefly 
resuspended in a 1× binding buffer before incubation 
with annexin V-FITC and propidium iodide according 
to the manufacturer’s instructions. Flow cytometry was 
performed using a FACScan flow cytometer (Becton–
Dickinson), with analysis using FLOW-JO software 
(Tree Star, Ashland, OR) to assess the Annexin-positive 
cell population.
Caspase enzymatic activity assay and use of irreversible 
caspase inhibitors
Enzymatic activities of caspases-3, -8, and -9 were deter-
mined using each respective fluorogenic substrate (Cal-
biochem, EMD Biosciences, San Diego, CA). Protein 
extract (20  µg) was incubated in a reaction buffer con-
taining 50  mM Tris (pH 7.5) and caspase substrate at a 
final concentration of 20 µM in 96-well plates. After 3-h 
incubation at 37 °C, liberated fluorescent 7-amido-4-me-
thyl-coumarin groups were quantified using a multi-well 
plate VersaFluorTM Fluorometer with an excitation filter 
of 380 nm and an emission filter of 460 nm (Bio-Rad Lab-
oratories, Hercules, CA). When irreversible inhibitors 
of caspases-3, -8, and -9 were used (Calbiochem, EMD 
Biosciences), each inhibitor was used at a final concen-
tration of 10 µM and incubated with the treatment group 
4  h before treatment with tocotrienol. Tocotrienol was 
then added to the media containing the inhibitor at the 
indicated final concentration and treated for the desired 
length of time.
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Western blot analysis
To prepare whole cell protein lysates, cells were seeded at 
1 × 106 cells per 100-mm tissue culture dish and treated 
the following day with δ-tocotrienol. After desired treat-
ment times, cells were collected, washed with PBS, pel-
leted, lysed on ice for 5 min, and then stored at − 20 °C. 
Tumor tissues were cut into small pieces and homog-
enized with tissue protein extraction reagent (T-PER, 
Pierce) and centrifuged at 10 000 RPM for 10  min. !e 
extracted proteins were stored at − 20 °C. Protein concen-
tration was determined to ensure equal protein loading. 
Protein extracts were resolved using a 12.5% SDS-PAGE 
gel and then transferred to nitrocellulose membrane. 
Protein separation was briefly assessed using Ponceau 
S solution (Pierce). Membranes were then washed with 
fresh Tris-buffered saline containing .1% Tween 20 (1× 
TBS-T) and blocked with 5% nonfat dry milk solution. 
Primary antibodies were incubated in 3% BSA solu-
tion either overnight at 4  °C or for 1  h at 25  °C. When 
reblotting was necessary, antibodies were stripped from 
membrane by incubating with Western blot stripping 
buffer (Pierce) for 0.5  h at 25  °C. High-affinity antibod-
ies were stripped from membrane by washing for 5 min 
with a 0.2 M NaOH solution 3 times at 25 °C, followed by 
3 × 5-min washes with deionized water. Membranes were 
thoroughly washed in 1× TBS-T at 25 °C and incubated 
with secondary antibody (horseradish peroxidase-conju-
gated) at 1:2000 dilutions for 1  h at room temperature. 
!e washed blot was then treated with SuperSignal West 
Pico chemiluminescent substrate (Pierce Biotech) for 
positive antibody reaction. Membranes were exposed to 
x-ray film for visualization and densitometric quantiza-
tion of protein bands using AlphaEaseFC software (Alpha 
Innotech, Santa Clara, CA).
Generation of MiaPaCa-2 cells stably expressing 
GFP-labeled c-FLIPs
MiaPaCa-2 cells were transfected with a plasmid-con-
taining full-length open-reading frame cDNA of c-FLIPs 
fused with GFP at the C-terminus in a pCMV6-AC-GFP 
vector. MiaPaCa-2 cells transfected with the pCMV6-
AC-GFP vector containing GFP alone served as control. 
All transfections were performed using Lipofectamine™ 
2000 reagent (Invitrogen) at a 1  µg:1  µL DNA-to-Lipo-
fectamine 2000 ratio, per manufacturer’s instructions. 
Cells were selected for 2  weeks with G418 sulfate at a 
final concentration of 500 µg/mL.
Immunoprecipitation for detection of c-FLIP ubiquitination
Mia-FLIPs cells, stably expressing GFP-FLIPs, were trans-
fected with HA-ubiquitin plasmid (Addgene) using the 
Lipofectamine 2000 transfection reagent, in accordance 
with the manufacturer’s instructions. After 24  h, cells 
were treated with δ-tocotrienol alone (50 µM) or in com-
bination with MG-132 (25  µM) for 6  h and then lysed 
for immunoprecipitation of ubiquitin-bound c-FLIPs, 
using GFP polyclonal antibody (Abcam). Harvested 
cells were washed 3 times with ice-cold PBS and resus-
pended in 1 mL of ice-cold CelLytic™ M cell lysis reagent 
(Sigma) containing protease inhibitors. Cleared lysates 
were then incubated with 10 µg of GFP polyclonal anti-
body and 100 μL of 50% slurry of Protein A/G Agarose 
(Santa Cruz, sc-2003) into the lysate, and the mixture was 
rotated overnight at 4 °C. Beads were washed three times 
with lysate buffer followed by spinning for 5 s at 10,000 g. 
After the washes, 50 μL of 1 × sample buffer was added to 
the bead pellet and boiled at 100 °C for 5 min followed by 
the detection of ubiquitin-bound c-FLIPs with Western 
blotting using anti-HA antibody (Santa Cruz, sc-57592).
Quantitative PCR analysis
RNA was isolated from cells using the AllPrep RNA/Pro-
tein kit from Qiagen (Germantown, MD), in accordance 
with the manufacturer’s instructions. RNA extracts were 
analyzed by quantitative PCR by the Molecular Biology 
Core at the Moffitt Cancer Center using the TaqMan 
gene expression assay kit to assess c-FLIP mRNA levels. 
18S rRNA was used as an internal control.
In vivo tumor xenograft model
MiaPaCa-2 cells were harvested and resuspended in fresh 
media, and the number of viable cells was determined. 
Cells were then injected subcutaneously into flanks of 
NIH-III nude SCID mice (Charles River Laboratories, 
Boston, MA) at a density of 1 × 106  cells/per flank in a 
1:1 solution of PBS to Matrigel Matrix (BD BioSciences). 
Mice were randomized into control and treated groups, 
with controls receiving ethanol-extracted olive oil (vehi-
cle control) alone and treated mice receiving 200 mg/kg 
of δ-tocotrienol in vehicle. All treatments were adminis-
tered orally by gavage 12 times/week (weekdays, 2×/day; 
weekends, 1×/day), and mouse weights were recorded 
twice per week.
For the drug combination (TRAIL and VEDT) experi-
ment, female Athymic nude mice (n = 20) were injected 
subcutaneously with MiaPaCa-2 cells into flanks at a den-
sity of 1 × 106 cells/per flank in a 1:1 solution of PBS to 
Matrigel Matrix. Mice were randomized into 4 groups of 
5 animals each and treated as follows: (Group 1) Vehicle 
control mice were given orally ethanol-extracted olive oil 
twice a day and intraperitoneal (IP) injection of PBS on 
alternate days for 4 weeks, (Group 2) TRAIL mice were 
injected with TRAIL 20  µg/kg IP on alternate days for 
4 weeks, (Group 3) VEDT mice were given orally VEDT 
(200  mg/kg) twice a day for 4  weeks, and (Group 4) 
TRAIL + VEDT mice were injected with TRAIL 20 µg/kg 
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IP on alternate days and VEDT orally (200 mg/kg) twice 
a day for 4 weeks. Tumors were measured daily with cali-
pers using the formula T = L × W × [(L + W)/2] × 0.5236, 
where T is tumor volume, L is smallest tumor diameter, 
and W is largest tumor diameter. Animal data are repre-
sentative of 2 independent experiments. Animals were 
sacrificed after 4 weeks and tumor weights were recorded 
and half tumor tissues were fixed in buffered formalin 
for histology staining and the other half were immersed 
in liquid nitrogen then frozen at − 80 °C for further bio-
chemical analyses.
Histological and immunohistochemical analyses
At the end of the study, mice were killed, and tumors 
were extracted and embedded in paraffin sections for 
further analyses. Immunohistochemistry was performed 
using the Ventana Discovery XT automated system (Ven-
tana Medical Systems, Tucson, AZ), per manufacturer’s 
protocol, with proprietary reagents. Slides were depar-
affinized on the automated system with EZ Prep solution. 
Sections were heated for antigen retrieval. For immu-
nohistochemistry, tissue sections were incubated with 
antibodies. Detection was performed using the Ventana 
OmniMap kit. Apoptosis by TUNEL staining, cleaved 
caspase-8, cleaved caspase-3, and Ki-67 staining and 
hematoxylin and eosin staining were quantified by the 
Moffitt Anatomic Pathology Core.
Statistical analyses
Data, expressed as mean ± standard error of the means, 
were analyzed statistically using unpaired t-tests or 1-way 
analysis of variance (ANOVA), as appropriate. ANOVA 
was followed by Duncan’s multiple range tests using 
SAS statistical software for comparisons between differ-
ent treatment groups. Analyses of in vivo data were per-
formed using the GraphPad Prism program (GraphPad 
Software, San Diego, CA) on the entire tumor growth 
curve using a 2-way ANOVA, mixed-effect model for 
repeated measures, with respect to the column factor 
corresponding to δ-tocotrienol treatment. Statistical sig-
nificance was set at P < .05.
Results
VEDT inhibits the growth of human pancreatic cancer cells 
in vitro and in vivo and induces apoptosis
We first examined whether VEDT alone could inhibit 
the survival of a panel of human pancreatic cancer cells. 
Immortalized HPNE cells and HPNE cells transformed 
with oncogenic K-Ras (HPNE K-Ras) served as controls. 
VEDT significantly inhibited the viability of 5 human 
pancreatic cancer cell lines and the HPNE K-Ras cell line 
in a dose-dependent manner. In contrast, HPNE cells 
were markedly less sensitive to VEDT (Fig. 1a).
Because decreased cell survival may be caused by 
many processes (i.e., autophagy, anoikis, apoptosis, 
necrosis), we next investigated whether VEDT survival 
inhibition could be attributed to increased apoptosis. 
Using TUNEL staining, which detects apoptotic DNA 
fragmentation, we examined VEDT’s ability to induce 
apoptosis in MiaPaCa-2 cells. VEDT administration 
resulted in a statistically significant (P < .001) induction 
of apoptosis in MiaPaCa-2 cells (Fig.  1b). In contrast, 
normal HPDE6-C7 cells were spared from apoptotic 
cell death at the equivalent dose of 20  µM, indicating 
that VEDT selectively exhibits activity against malig-
nantly transformed cells. To verify these findings 
in vivo, we examined the proapoptotic activity of VEDT 
in a human pancreatic cancer xenograft mouse model, 
as described previously [16]. MiaPaCa-2 cells were 
injected subcutaneously into NIH-III nude mice and 
allowed to reach a volume of 100 mm3. Immunohisto-
chemistry of paraffin-embedded tumors of treated mice 
showed that VEDT not only caused a statistically signif-
icant inhibition of tumor growth compared with vehicle 
(P < .007) but also resulted in significant (P < .05) induc-
tion of apoptosis in tumor tissues (Fig. 1c, d).
VEDT induces caspase-8-dependent apoptosis in human 
pancreatic cancer cells
To determine the mechanism by which VEDT induces 
apoptosis in pancreatic cancer cells, we measured 
VEDT’s effects on the activation of intracellular caspase 
cascades and the dependence of VEDT-induced apop-
tosis on caspase activation. Cleavage of procaspase-8 
and procaspase-3 were detected in VEDT-treated 
MiaPaCa-2, BxPC-3, and SW1990 cell lines. Although 
procaspase-9 was detected in these cells, cleavage of 
procaspase-9 was not detected (Fig.  2a). Consistent 
with the immunoblot detection, caspase-8 and cas-
pase-3 enzyme activities were both increased from 6 
to 24 h following VEDT treatment in MiaPaCa-2 cells; 
however, caspase-9 activity was not significantly altered 
after VEDT treatment (Fig. 2b). Furthermore, as shown 
in Fig.  3c, inhibition of caspase-8 and caspase-3 acti-
vation using Z-Ile-Glu(OMe)-!r-Asp(OMe)-CH2F 
and Ac-Asp-Glu-Val-Asp-CMK resulted in significant 
inhibition of VEDT-induced apoptosis in MiaPaCa-2 
cells, whereas inhibition of caspase-9 activation using 
Z-Leu-Glu(OMe)-His-Asp(OMe)-CH2F resulted in no 
effect on VEDT-induced apoptosis in these cells. More-
over, significant induction of cleaved caspase-3 was also 
detected in MiaPaCa-2 xenograft tumors treated with 
VEDT (Fig.  2d). !us, these results collectively show 
that VEDT induces caspase-8-dependent apoptosis.
Page 6 of 15Francois et al. Cancer Cell Int          (2019) 19:189 
VEDT augments TRAIL-mediated apoptosis in human 
pancreatic cancer in vitro and in vivo
If VEDT-induced apoptosis is caspase-8-dependent, we 
speculated that adding exogenous recombinant TRAIL 
to VEDT treatment would result in enhanced apop-
tosis induction. To test this hypothesis, we treated 4 
human pancreatic cancer cell lines (MiaPaCa-2, BxPC-
3, SW1990, and Panc-1) with VEDT alone, TRAIL 
alone, or both drugs combined and then accessed 
cell survival, caspase-3 enzyme activity, and apopto-
sis. As presented in Fig. 3a, the combination of VEDT 
at concentrations of 10 to 50  μM with TRAIL (25 or 
50  ng/mL) was more effective in decreasing tumor 
cell number than either agent alone. For example, in 
MiaPaCa-2, both VEDT alone (at 25  μM) and TRAIL 
alone (at 25 ng/mL) decreased cell numbers by 15% and 
30%, respectively. However, combining the 2 agents 
reduced cell numbers by > 50%; more than the sum of 
each agent’s effects alone. Measuring caspase-3 enzyme 
activity further highlights the effects of combining 
VEDT and TRAIL on apoptosis induction. Figure  3b 
shows that the combination of 50 μM VEDT and 25 ng/
mL TRAIL more effectively activated caspase-3 enzyme 
activity than either agent alone in all pancreatic can-
cer cell lines examined. For example, in SW1990 cells, 
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Fig. 1 The effects of VEDT on survival, apoptosis induction, and tumor tissues in mice. a Effect of VEDT dose response on survival at 72 h in panel 
of human pancreatic cancer cell lines (AsPc-1, BxPc-3, MiaPaCa-2, Panc-1, and SW1990) and a pair of immortalized HPNE containing vector alone 
(HPNE-V) or transformed with oncogenic KRAS (HPNE-KRAS). Points, means; bars, standard error (n = 3–5, *P < .001, #P < .05). b Effect of δ-tocotrienol 
(VEDT; 20 µM) on induction of apoptosis, as measured by TUNEL staining in HPDE6-C7 immortalized human pancreatic ductal epithelial cells and 
MiaPaCa-2 pancreatic cancer cells. Ethanol served as vehicle control. VEDT significantly induced apoptosis in MiaPaCa-2 cells. Columns, means; 
bars, standard deviation (n = 4, ***P < .001). c Growth inhibition of subcutaneous MiaPaCa-2 xenografts in NIH-III mice treated orally twice daily 
with 200 mg/kg VEDT. Olive oil served as vehicle control. Points, means; bars, standard deviation (n = 5, P < .007). d Effect of VEDT on apoptosis 
(TUNEL) and cleaved caspase 8 in formalin-fixed, paraffin-embedded MiaPaCa-2 xenograft tumor tissues in mice. H&E, hematoxylin and eosin. VEDT 
significantly induced apoptosis (P < .05) compared with vehicle-treated mice (n = 5)
Page 7 of 15Francois et al. Cancer Cell Int          (2019) 19:189 
activity by 250- and 300-fold over controls; however, 
the 2 agents combined increased enzyme activity by 
> 1000-fold, which was greater than the sum of the 
effects of each agent alone. Using Western blotting, we 
also detected the strongest bands of cleaved caspases 
and poly ADP ribose polymerase (PARP) or the most 
reduction of procaspases and PARP in cells exposed 
to VEDT + TRAIL compared with VEDT or TRAIL 
alone (Fig.  3c). Moreover, we used annexin V stain-
ing to detect apoptosis in MiaPaCa-2 and Panc-1 cells 
exposed to VEDT + TRAIL. During 24-h treatment, 
VEDT + TRAIL combined was much more effective in 
inducing apoptosis (44% and 49%) than TRAIL (15% 
and 23%) or VEDT (20% and 25%) alone (Fig.  3d and 
Additional file  1: Figure S1). Collectively, these results 
clearly indicate that VEDT synergized with TRAIL to 
augment induction of apoptosis in human pancre-
atic cancer cells. To verify these findings in  vivo, we 
examined VEDT’s antitumor and proapoptotic activ-
ity in a human pancreatic cancer xenograft mouse 
model. MiaPaCa-2 cells were injected subcutaneously 
into Athymic nude mice and allowed to reach a vol-
ume of 100  mm3, and the single-drug treatments and 
the combination were given for 4  weeks. Tumor vol-
ume was recorded every week, and after 4  weeks, the 
tumor weights were recorded and the tumor tissues 
were processed to analyze c-FLIP and apoptotic pro-
tein expression by Western Blot. Tumor volume and 
MiaPaCa-2 BxPc-3 SW 1990 HPDE6-C7
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Fig. 2 Western blot analyses of caspases. a Western blot analyses of caspases (casp) -3, -8, and -9, cleavage in MiaPaCa-2, BxPc-3, SW1990 pancreatic 
cancer cells, and HPDE6-C7 immortalized human pancreatic ductal epithelial cells treated with VEDT for 0, 6, 12, or 24 h. β-Actin served as loading 
control. b Enzymatic activities of caspases-3, -8, and -9 in MiaPaCa-2 cells following VEDT treatment at indicated time points. Columns, means; bars, 
standard deviation (n = 4, *P < .05, **P < .01, and ***P < .001). c Effect of VEDT induction of apoptosis by pretreatment with covalent irreversible 
inhibitors of caspases-3, -8, and -9 (C3i, C8i, and C9i). Dimethyl sulfoxide served as vehicle control for each inhibitor. NS not significant. Columns, 
means; bars, standard deviation (n = 4, **P < .01 compared with untreated cells). d Immunohistochemical analysis of cleaved caspase-8 and cleaved 
caspase 3 in MiaPaCa-2 xenograft tumors. H&E, hematoxylin and eosin. VEDT treatment increased cleaved caspase-8 staining compared to vehicle 
(n = 5)
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weight were significantly reduced in mice previously 
treated with TRAIL (cP < .001 and aP < .02) and VEDT 
(cP < .001 and aP < .02) for 4  weeks compared to those 
treated with vehicle (Fig. 4a, b). However, the combina-
tion of the 2 drugs resulted in a more significant inhi-
bition of tumor volume (cP < .001) and weight (bP < .01) 
than for tumors treated with vehicle or either drug 
alone (dP < .02 and cP < .05). !e Western blot data show 
that TRAIL and VEDT induced apoptosis (cleaved cas-
pase-8, cleaved caspase-3, and cleaved PARP), and the 
combination induced greater apoptosis in the tumor 
tissues than either drug alone (Fig. 4c). VEDT but not 
TRAIL depleted the c-FLIP expression in tumor tissues 
compared to vehicle. However, combining the 2 drugs 
profoundly depleted the c-FLIP expression in tumor 
tissues (Fig. 4c). !e histological data in tumor tissues 
further confirmed that VEDT significantly enhanced 
the TRAIL-induced apoptosis (cleaved caspase-8) 
and inhibition of tumor cell proliferation (Ki-67), as 




TRAIL:   - - +     +     - - +     +      - - +    +        - - +    +
VEDT:    - +     - +     - +       - +      - +     - +        - +      - +
























1 0 0 0
1 5 0 0 B xP c -3
SW 1 9 9 0
P A NC -1
M iaP aC a -2





















M ia P a C a -2




























































SW 19 9 0

























































Fig. 3 The effects of TRAIL and VEDT on cell survival. a Effect of TRAIL alone (25 and 50 ng/mL) or in combination with VEDT at multiple 
concentrations (10, 25, 50 μM) on cell survival at 24 h in panel of human pancreatic cancer cell lines. Columns, means; bars, standard deviation 
(n = 3, *P < .05 and **P < .01). b Effect of TRAIL alone or in combination with VEDT on the enzymatic activity of caspase-3 in panel of human 
pancreatic cancer cell lines after 24 h. Columns, means; bars, standard deviation (n = 3, *P < .05 and **P < .01). c Western blot analysis of cleavage of 
caspase-8, caspase-3, and PARP (CF = cleaved fragment) in a panel of human pancreatic cancer cell lines following treatment with TRAIL alone or in 
combination with VEDT for 24 h (n = 3). β-Actin served as loading control. d Flow cytometry analysis of apoptosis as measured by annexin V staining 
following treatment with TRAIL alone (25 ng/mL) or in combination with VEDT (50 μM) in MiaPaCa-2 cells (n = 3). In annexin V assay, percentages 
of positive cells in the top right and bottom right quadrants were added to get the total apoptotic cells. *P < .001 compared with untreated cells; 
**P < .01 compared with untreated cells
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VEDT induces apoptosis and augments TRAIL activity 
through down-regulation of c-FLIPS in human pancreatic 
cancer cells
!e mechanisms by which agents augment TRAIL-
induced apoptosis include modulation of proteins 
upstream to caspase-8 activation. !ese mechanisms 
include induction of the death receptors DR4 and/or 
DR5, decreased expression of decoy receptors DCR1, 
DCR2, and DCR3, and decreased expression of the 
short isoform of c-FLIP (c-FLIPs), which inhibits apop-
tosis by preventing the recruitment of caspase-8 into the 
death-inducing signaling complex. !us we determined 
whether VEDT modulated DCR1, DCR2, DCR3, DR4, 
DR5, or c-FLIPs expression in human pancreatic cancer 
cells by Western blot analysis. We detected a consistent 
time-dependent decrease in  FLIPs expression that pre-
ceded VEDT-induced activation of caspase-8 in Mia-
PaCa-2, BxPC-3, and SW1990 cells exposed to VEDT, 
which occurred at 6 h and was sustained for at least 16 h 
(Fig. 5a). In contrast, there was no consistent modulation 
of DCR1, DCR2, DCR3, DR4, or DR5 by VEDT.
We next investigated whether inhibition of c-FLIPs is 
required for induction of apoptosis by VEDT using Mia-
PaCa-2 cells transfected with pCMV6-AV-GFP vector-
containing c-FLIPs tagged with GFP. Figure 5b shows that 
we observed a statistically significant induction of apop-
tosis in mock and vector-transfected cells treated with 
VEDT (P < .01 and P < .001). Importantly, transient over-
expression of c-FLIPs not only abrogated VEDT-induced 
apoptosis compared with vehicle (not significant) but 
also rescued endogenous c-FLIPs inhibition compared 
with vector transfection. To further study the role of 
c-FLIPs, we created MiaPaCa-2 cells stably overexpress-
ing c-FLIPs (Mia-FLIP) or GFP vector alone (Mia-GFP; 
Additional file  2: Figure S2B–E). !is enforced ectopic 
overexpression of c-FLIPs significantly abrogated VEDT 
induction of caspase-8 enzymatic activity and inhibi-
tion of survival (Fig.  5c). Moreover, c-FLIPs overexpres-
sion in MiaPaca-2 cells resulted in inhibition of VEDT 
augmentation of TRAIL-induced inhibition of cell sur-
vival in pancreatic cancer cells. For example, TRAIL 
(25  ng/L) and VEDT (25  μM) treatment of MiaPaCa-2 
cells with GFP vector decreased cell numbers by 30% and 
20%, respectively, whereas the combination decreased 
cell number by 45%. In contrast, the same concentra-
tion of the agents in MiaPaCa-2 cells expressing c-FLIPs 
decreased cell numbers by 10% and 5%, respectively, with 
the combination decreasing cell numbers by only 20% in 
these cells (Fig. 5d).
VEDT down-regulates c-FLIPs through promoting 
ubiquitin/proteasome-mediated degradation
To determine how VEDT regulates c-FLIPs, we investi-
gated VEDT’s effect on c-FLIPs transcription and trans-
lation. Regulation of c-FLIPs has been shown to occur 
at the level of transcription and translation, as well as 
post-transitionally at the protein level [24]. To this end, 
mRNA levels from VEDT-treated MiaPaCa-2 and BxPc-3 
cells were analyzed by quantitative PCR at 6 h, at which 
point protein levels of c-FLIPs seemed to first decrease. 
c-FLIPs mRNA levels were normalized to those of 18S 
rRNA (internal control). At 6  h after VEDT treatment, 
we observed that c-FLIPs messenger RNA (mRNA) lev-
els had not decreased but had actually increased versus 
baseline (Fig. 6a).
To validate our findings, we investigated the abil-
ity of VEDT to down-regulate c-FLIPs protein expres-
sion in the absence of mRNA translation using the 
protein synthesis inhibitor cyclohexamide. VEDT was 
found to accelerate c-FLIPs turnover compared with 
turnover observed with cyclohexamide alone (Fig. 6b). 
Next, we sought to identify whether proteasomal 
Fig. 4 The effects of TRAIL and VEDT on tumor volume. a Effect of TRAIL (20 µg/Kg intraperitoneally) on alternate days and VEDT (200 mg/kg, Orally) 
twice a day and combination of the two drugs for 4 weeks on MiaPaPa-2 tumor volume in Athymic nude mice. The tumor volume significantly 
reduced in TRAIL and VEDT treated mice for 4 weeks compared to vehicle (cP < .001 and cP < .001). However the combination of the two drugs 
resulted in a more significant inhibition of tumor volume compared to vehicle (cP < .001) or either drug alone (dP < .02). b Effect of TRAIL (20 µg/Kg 
intraperitoneally) on alternate days and VEDT (200 mg/kg, Orally) twice a day and combination of the two drugs for 4 weeks on MiaPaPa-2 tumor 
weight in athymic nude mice. The tumor weights were significantly reduced in TRAIL and VEDT (aP < .02) treated mice for 4 weeks compared to 
vehicle (aP < .02 and a0P < .02). However, the combination of the two drugs resulted in a more significant inhibition of tumor weight compared to 
vehicle (bP < .01) or either drug alone (cP < .05). c Western blot analyses of cleaved caspase-8, cleaved caspase-3, cleaved PARP, and c-FLIPs in tumor 
tissues following treatment with TRAIL alone or in combination with VEDT for 4 weeks (n = 5). β-Actin served as loading control. TRAIL and VEDT 
alone induced apoptosis (elevated cleaved caspase-8, cleaved caspase-3, and cleaved PARP). Greater induction of apoptosis was noted in tumor 
tissues following combined drug treatment than with either drug alone. VEDT alone and in combination with TRAIL but not TRAIL alone depleted 
tumor tissue c-FLIPs expression. d Histological data depicting the Ki-67, cleaved caspase-3, and cleaved caspase-8 in tumor tissues following 
treatment with TRAIL (T) alone or in combination with VEDT (DT3) for 4 weeks (n = 5). e Greater and significant induction of apoptosis (cleaved 
caspase-8, bP < .001) and inhibition of tumor cell proliferation (Ki-67, bP < .001) was noted in tumor tissues following combined drug treatment 
than with either drug alone. VEDT alone significantly induced cleaved caspase 3 compared to vehicle (bP < .001) and was greater than TRAIL-alone 
treatment (cP < .001). The combination significantly induced cleaved caspase 3 compared to vehicle (aP < .01) and compared to TRAIL alone (dP < .05)
(See figure on previous page.)
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degradation could be implicated in VEDT down-regu-
lation of c-FLIPs. We found that inhibition of c-FLIPs 
could be prevented by pretreatment with the pan-pro-
tease inhibitor MG132 in all cell lines tested (Fig.  6c). 
Because ubiquitination has been identified as an impor-
tant event associated with proteasomal degradation 
[25], we next transfected human influenza HA-tagged 
ubiquitin into MiaPaCa-2 cells stably overexpressing 
GFP-tagged c-FLIPs. Using co-immunoprecipitation 
techniques, we evaluated the fraction of ubiquitin-
bound c-FLIPs. As indicated in Fig. 6d, treatment with 
VEDT resulted in a marked shift in the fraction of ubiq-
uitin-bound c-FLIPs in the presence of MG-132 when 
compared to that of MG-132 alone. Collectively, these 
data support the concept that VEDT decreased c-FLIP 
levels through promoting ubiquitin/proteasome-medi-
ated degradation of c-FLIP.
Potencies of vitamin E compounds in inhibiting cell survival 
and enhancing cell death receptor-mediated apoptosis are 
associated with their abilities to down-regulate c-FLIP
We previously demonstrated that VEDT is the most 
bioactive of all of the naturally occurring vitamin E ana-
logs (Additional file 3: Figure S3A) [16]. Here, we report 
that VEDT is the most powerful vitamin E inhibitor of 
cell survival and c-FLIP protein expression in pancre-
atic cancer cells. Of note, c-FLIP down-regulation was 
directly associated with the ability of each vitamin E 
compound to inhibit cell survival (Additional file  3: 
Figure S3B, C). In addition, VEDT also augmented 
TRAIL-induced cell death in HPNE-Kras cells but not 
in normal HPNE-vector cells (Additional file  2: Figure 
S2A).
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Fig. 5 The effect of VEDT on cell death and survival. a Time course of VEDT activity on decoy receptors and death receptor pathway (DR4, DR5, 
DCR1, DCR2, DCR3) and c-FLIPs in panel of pancreatic cancer cells by Western blot (n = 3). b Effect of transient ectopic transfection of c-FLIPs in 
pCMV6-AC-GFP plasmid vector on apoptosis in MiaPaCa-2 cells treated with VEDT for 24 h as measured by TUNEL and quantified by analytic 
microscopy (inset). Columns, means; bars, standard deviation (n = 3, **P < .01 and ***P < .001). c Effect of VEDT on caspase-8 enzymatic activity in 
Mia-GFP and Mia-FLIP cells. Columns, means; bars, standard deviation (n = 3, *P < .001 and ***P < .05). d Effect of VEDT on survival in Mia-GFP and 
Mia-FLIP cells. Columns, means; bars, standard deviation (n = 3, *P < .001, **P < .01, and ***P < .05)
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Discussion
Pancreatic cancer is highly aggressive, with only 6% of 
patients surviving 5  years after diagnosis. Suppression 
of programed cell death is a hallmark of this cancer, 
which it displays as increased viability and resistance to 
cytotoxic therapies [26]. One example of this resistance 
to therapy is pancreatic cancer’s varied sensitivity to 
TRAIL, a tumor-selective cytokine, which activates the 
extrinsic apoptotic pathway [27–31]. !erefore, there is 
an important need for proapoptotic agents that can sen-
sitize pancreatic ductal adenocarcinoma cells to TRAIL 
and thereby overcome pancreatic cancer resistance to 
apoptosis. One intriguing finding that has been shown 
consistently by our group and others is the selective kill-
ing of pancreatic cancer cells by VEDT [5, 16, 19–21]. 
We have also shown selective induction of apoptosis by 
VEDT of pancreatic-transformed and malignant epithe-
lial cells but not normal immortalized human pancreatic 
ductal epithelial cells [16, 19]. Additionally, our animal 
studies showed that VEDT not only caused a statistically 
significant inhibition of tumor growth but also resulted 
in apoptosis of tumor tissues [16, 20, 21]. !ese results 
clearly demonstrate that induction of apoptosis is impli-
cated in the antitumor activity of VEDT.
In the current study, we found that VEDT alone trig-
gered a caspase-8-dependent apoptosis in pancreatic 
cancer cells; however, when combined with TRAIL, 
VEDT significantly augmented and potentiated the 
TRAIL-induced apoptosis of pancreatic cancer cells. 
Specifically, we were able to demonstrate in  vitro and 
in vivo increased cleaved caspase-8 and caspase-3 and 
induction of apoptotic cell death with VEDT treatment 
versus controls. Conversely, pharmacological inhibi-
tion of caspase-8 and caspase-3 demonstrated signifi-
cant attenuation of VEDT-induced apoptosis. Together, 
these results strongly suggest that VEDT induces apop-
tosis through activation of the caspase-8 cascade. !e 
role of caspase-8 in death receptor-mediated apopto-
sis has been extensively studied [24, 32, 33]. Interest-
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Fig. 6 The effect of VEDT on c-FLIP. a Effect of VEDT treatment on c-FLIP messenger RNA levels in MiaPaCa-2 and BxPc-3 cells at 6 h. 18S rRNA 
served as internal control for each sample (n = 3). b Half-life of c-FLIPs protein in MiaPaCa-2 cells as determined by cyclohexamide (CHX) (25 µg/
ml) pretreatment for the indicated duration, following 12-hour treatment with either vehicle (ethanol) or VEDT (n = 3). c Effect of MG132 protease 
inhibitor on c-FLIP protein levels in presence or absence of VEDT in a panel of pancreatic cancer cell lines (MiaPaCa-2, SW1990, BxPc-3 and Panc-1). 
The cells were pretreated with MG132 (25 µM) for 6 h followed by VEDT treatment for 24 h (n = 3). d Effect of MG132 protease inhibitor on 
ubiquitin-bound c-FLIP in the presence or absence of VEDT in MiaPaCa-2 cells. The cells were pretreated with MG132 (25 µM) for 6 h followed by 
VEDT treatment for 24 h (n = 3)
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to express all of the proteins of the extrinsic apoptotic 
pathway, most cell lines remain relatively insensitive to 
TRAIL-induced apoptosis. Both recombinant and anti-
body-based TRAIL therapies have been developed to 
date for the treatment of many cancers, but resistance 
to death receptor-mediated apoptosis remains a signifi-
cant barrier in the field of pancreatic cancer [34].
A possible molecular target for VEDT is c-FLIPs, an 
inhibitor of caspase-8 in pancreatic cancer cells. We had 
shown that VEDT but not tocopherols augment TRAIL 
activity (unpublished data). Our data show that VEDT 
decreased c-FLIPs levels without consistently modulat-
ing the expression of decoy death receptors 1, 2, and 
3 or death receptors 4 and 5. Furthermore, VEDT was 
found to inhibit c-FLIPs expression and induce cas-
pase-8-dependent apoptosis in pancreatic cancer cells, 
followed by caspase-3 and PARP1 cleavage in a time-
dependent manner. !e activation of caspases-8 and 
-3 were required for VEDT induction of apoptosis, as 
demonstrated by rescue with specific caspase inhibi-
tors. Moreover, the growth of pancreatic xenograft 
tumors in mice was significantly inhibited when treated 
with VEDT. !is inhibition was also accompanied by 
an induction of apoptosis in tumors and depletion of 
c-FLIPs protein expression. Although VEDT inhibited 
c-FLIPs protein levels by 6  h, mRNA levels were actu-
ally increased at this time point, suggesting that VEDT 
may be inhibiting c-FLIPs through protein degradation. 
From these analyses, we concluded that the mechanism 
of c-FLIPs down-regulation is unlikely caused by tran-
scriptional repression but rather an ubiquitin-mediated, 
proteasome-dependent process. Moreover, ferroptosis 
is a newly discovered type of cell death that differs from 
traditional apoptosis and necrosis and results from iron-
dependent lipid peroxide accumulation and autophagy 
[35, 36]. Pancreatic ductal adenocarcinoma with a 
mutant KRas gene is more susceptible to ferroptosis, 
and it might be related to the tumorigenesis of pancre-
atic carcinoma [37]. !erefore, VEDT may kill pancre-
atic cancer cells through ferroptosis. !is possibility will 
be investigated in our future studies.
Conclusions
We showed that VEDT decreased c-FLIP levels by pro-
moting ubiquitin/proteasome-mediated degradation 
of c-FLIP. In summary, our data indicate that VEDT 
down-regulates c-FLIPs, an inhibitor of caspase-8 acti-
vation through protein degradation, and induces apop-
tosis through activation of caspase-8 and caspase-3. 
!is works suggests that VEDT should be evaluated 
for targeting programed cell death in pancreatic cancer 
cells.
Additional "les
Additional "le 1: Fig. S1. Chemical structures of vitamin E analogs and 
effect of 8 members of the vitamin E family on cell survival in MiaPaCa-2 
cells. (A) Chemical structures of the vitamin E analogs. (B) Effect of the 8 
members of the vitamin E family on cell survival in MiaPaCa-2 cells. Points, 
means; bars, standard error (n = 3-5, *P < .001, **P < .01). (C) Effect of the 8 
members of the vitamin E family on c-FLIP expression in MiaPaCa-2 cells 
(n = 3). 
Additional "le 2: Fig. S2. Effects of VEDT and TRAIL on cell death and 
Western blot analyses. (A) Effect of VEDT (50 µM) and TRAIL (25 ng/mL) 
alone and in combination on cell death (Trypan blue) of immortalized 
human pancreatic normal epithelial (HPNE-vector) cells and HPNE-Kras 
cells. VEDT, TRAIL, or the combination of the 2 drugs did not cause 
significant cell death in HPNE-vector cells (n = 3-5). VEDT and TRAIL alone 
significantly induced cell death compared to vehicle (aP < .02 and bP < .05, 
respectively) in HPNE-Kras cells (n = 3-5). However, greater significant cell 
death occurred when agents were combined than with vehicle (cP < .01) 
and either drug alone (dP < .05). (B) Western blot analyses of endogenous 
and exogenous c-FLIPs protein expression in MiaPaCa-2 cells. Mock 
transfection and pCMV6-AC-GFP vector transfections served as internal 
controls, whereas β-actin served as loading control. c-FLIPs expression is 
shown in parental MiaPaCa-2 cells and in MiaPaCa-2 cells stably express-
ing pCMV6-AC-GFP vector alone (Mia-GFP) or containing c-FLIPs (Mia-FLIP) 
(n = 3). (C) VEDT inhibited c-FLIPs expression in Mia-GFP cells compared 
to vehicle (V) after 24 h and the expression was rescued in Mia-FLIP cells 
(n = 3). (D) VEDT (T) induced apoptosis (PARP cleavage) in (Mia-GFP) cells 
compared to vehicle (V) after 24 h. CF = cleaved fragment (n = 3) and 
(E) Immunofluorescence staining of apoptosis (TUNEL) show that VEDT 
induced apoptosis in (Mia-GFP) cells compared to vehicle (Veh) after 24 h 
and apoptosis was rescued in (Mia-FLIP) cells compared to vehicle (Veh) 
(n = 3). 
Additional "le 3: Fig. S3.Effects of VEDT and TRAIL on apoptosis Effects 
of VEDT (50 µM) and TRAIL (25 ng/mL) alone and in combination on apop-
tosis (Annexin V/PI) of Panc-1 cells. VEDT and TRAIL induced apoptosis 
(25% and 23%, respectively) compared to vehicle in Panc-1 cells. However, 
greater apoptosis occurred when the 2 drugs were combined than 
occurred with vehicle alone (49%) in Panc-1 cells.
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